Clinical Trial Update: Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis [NA]

View source ↗

Summary

A clinical trial update notes a study exploring OCT imaging biomarkers to evaluate Ublituximab treatment response in relapsing-remitting multiple sclerosis, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ublituximab (ublituximab)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Multiple Sclerosis (MS) - Relapsing-remitting | NA | Status: NOT_YET_RECRUITING